Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Johannes Duell

Showing results (11-20 of 41) with videos related to

Pageof 5
Sort By:
Haematologica|February 1, 2015
GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6Leo Rasche, Johannes Duell, Inês C Castro, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 16, 2019
Functionally Defective T Cells After Chemotherapy of B-Cell Malignancies Can Be Activated by the Tetravalent Bispecific CD19/CD3 Antibody AFM11Johannes Duell, Dragana S Lukic, Margarete Karg, et al.
Mabs|April 16, 2015
A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cellsUwe Reusch, Johannes Duell, Kristina Ellwanger, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 24, 2024
Recent Advances in the Biology and CD123-Directed Treatment of Blastic Plasmacytoid Dendritic Cell NeoplasmNaveen Pemmaraju, Eric Deconinck, Priyanka Mehta, et al.
Blood Advances|June 13, 2022
Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy: a GLA/DRST studyNico Gagelmann, Gerald Georg Wulf, Johannes Duell, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 13, 2021
Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CTJohannes Duell, Franziska Krummenast, Andreas Schirbel, et al.
Molecular Imaging and Biology|August 1, 2024
Interobserver Agreement Rates on CXCR4-Directed PET/CT in Patients with Marginal Zone LymphomaRudolf A Werner, Yingjun Zhi, Niklas Dreher, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 9, 2023
Chemokine receptor-targeted PET/CT provides superior diagnostic performance in newly diagnosed marginal zone lymphoma patients: a head-to-head comparison with [<sup>18</sup>F]FDGAleksander Kosmala, Johannes Duell, Simone Schneid, et al.
Annals of Hematology|August 8, 2023
The addition of rituximab to chemotherapy improves overall survival in mantle cell lymphoma-a pooled trials analysisLuca Fischer, Linmiao Jiang, Joerg Thomas Bittenbring, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 3, 2020
Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple MyelomaMax S Topp, Johannes Duell, Gerhard Zugmaier, et al.
Pageof 5

Showing results (11-20 of 41) with videos related to

Sort By:
Pageof 5
Haematologica|February 1, 2015
GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6Leo Rasche, Johannes Duell, Inês C Castro, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 16, 2019
Functionally Defective T Cells After Chemotherapy of B-Cell Malignancies Can Be Activated by the Tetravalent Bispecific CD19/CD3 Antibody AFM11Johannes Duell, Dragana S Lukic, Margarete Karg, et al.
Mabs|April 16, 2015
A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cellsUwe Reusch, Johannes Duell, Kristina Ellwanger, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 24, 2024
Recent Advances in the Biology and CD123-Directed Treatment of Blastic Plasmacytoid Dendritic Cell NeoplasmNaveen Pemmaraju, Eric Deconinck, Priyanka Mehta, et al.
Blood Advances|June 13, 2022
Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy: a GLA/DRST studyNico Gagelmann, Gerald Georg Wulf, Johannes Duell, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 13, 2021
Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CTJohannes Duell, Franziska Krummenast, Andreas Schirbel, et al.
Molecular Imaging and Biology|August 1, 2024
Interobserver Agreement Rates on CXCR4-Directed PET/CT in Patients with Marginal Zone LymphomaRudolf A Werner, Yingjun Zhi, Niklas Dreher, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 9, 2023
Chemokine receptor-targeted PET/CT provides superior diagnostic performance in newly diagnosed marginal zone lymphoma patients: a head-to-head comparison with [<sup>18</sup>F]FDGAleksander Kosmala, Johannes Duell, Simone Schneid, et al.
Annals of Hematology|August 8, 2023
The addition of rituximab to chemotherapy improves overall survival in mantle cell lymphoma-a pooled trials analysisLuca Fischer, Linmiao Jiang, Joerg Thomas Bittenbring, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 3, 2020
Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple MyelomaMax S Topp, Johannes Duell, Gerhard Zugmaier, et al.
Pageof 5